RXRX

Company Overview — What Does RECURSION PHARMACEUTICALS, INC. Do?

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah. RECURSION PHARMACEUTICALS, INC. (RXRX) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Chistopher C. Gibson and employs approximately 400 people. With a market capitalization of $1.6B, RXRX is one of the notable companies in the Healthcare sector.

RECURSION PHARMACEUTICALS, INC. (RXRX) Stock Rating — Avoid (April 2026)

As of April 2026, RECURSION PHARMACEUTICALS, INC. receives a Avoid rating with a composite score of 22.0/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.RXRX ranks #4,237 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, RECURSION PHARMACEUTICALS, INC. ranks #761 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

RXRX Stock Price and 52-Week Range

RECURSION PHARMACEUTICALS, INC. (RXRX) currently trades at $3.30. The stock lost $0.01 (0.3%) in the most recent trading session. The 52-week high for RXRX is $7.18, which means the stock is currently trading -54.0% from its annual peak. The 52-week low is $2.98, putting the stock 10.7% above its annual trough. Recent trading volume was 8.6M shares, reflecting moderate market activity.

Is RXRX Overvalued or Undervalued? — Valuation Analysis

RECURSION PHARMACEUTICALS, INC. (RXRX) carries a value factor score of 15/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 1.49x, versus the sector average of 2.75x. The price-to-sales ratio is 25.83x, compared to 1.66x for the average Healthcare stock.

At current multiples, RECURSION PHARMACEUTICALS, INC. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

RECURSION PHARMACEUTICALS, INC. Profitability — ROE, Margins, and Quality Score

RECURSION PHARMACEUTICALS, INC. (RXRX) earns a quality factor score of 18/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -55.9%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -42.9% versus the sector average of -33.1%.

On a margin basis, RECURSION PHARMACEUTICALS, INC. reports gross margins of -45.8%, compared to 71.5% for the sector. The operating margin is -1479.8% (sector: -66.1%). Net profit margin stands at -1442.6%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -64.1% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

RXRX Debt, Balance Sheet, and Financial Health

RECURSION PHARMACEUTICALS, INC. has a debt-to-equity ratio of 30.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 5.50x, indicating strong short-term liquidity. Total debt on the balance sheet is $21M. Cash and equivalents stand at $660M.

RXRX has a beta of 2.30, meaning it is more volatile than the broader market — a $10,000 investment in RXRX would be expected to move 129.6% more than the S&P 500 on any given day. The stability factor score for RECURSION PHARMACEUTICALS, INC. is 25/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

RECURSION PHARMACEUTICALS, INC. Revenue and Earnings History — Quarterly Trend

In TTM 2026, RECURSION PHARMACEUTICALS, INC. reported revenue of $65M and earnings per share (EPS) of $-1.44. Net income for the quarter was $-632M. Gross margin was -45.8%. Operating income came in at $-638M.

In FY 2025, RECURSION PHARMACEUTICALS, INC. reported revenue of $75M and earnings per share (EPS) of $-1.44. Net income for the quarter was $-645M. Gross margin was 5.0%. Revenue grew 26.9% year-over-year compared to FY 2024. Operating income came in at $-648M.

In Q3 2025, RECURSION PHARMACEUTICALS, INC. reported revenue of $5M and earnings per share (EPS) of $-0.36. Net income for the quarter was $-162M. Gross margin was -183.8%. Revenue grew -80.2% year-over-year compared to Q3 2024. Operating income came in at $-172M.

In Q2 2025, RECURSION PHARMACEUTICALS, INC. reported revenue of $19M and earnings per share (EPS) of $-0.41. Net income for the quarter was $-172M. Gross margin was -4.9%. Revenue grew 33.3% year-over-year compared to Q2 2024. Operating income came in at $-176M.

Over the past 8 quarters, RECURSION PHARMACEUTICALS, INC. has demonstrated a growth trajectory, with revenue expanding from $14M to $65M. Investors analyzing RXRX stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

RXRX Dividend Yield and Income Analysis

RECURSION PHARMACEUTICALS, INC. (RXRX) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

RXRX Momentum and Technical Analysis Profile

RECURSION PHARMACEUTICALS, INC. (RXRX) has a momentum factor score of 17/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 39/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 37/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

RXRX vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, RECURSION PHARMACEUTICALS, INC. (RXRX) ranks #761 out of 838 stocks based on the Blank Capital composite score. This places RXRX in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing RXRX against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full RXRX vs S&P 500 (SPY) comparison to assess how RECURSION PHARMACEUTICALS, INC. stacks up against the broader market across all factor dimensions.

RXRX Next Earnings Date

No upcoming earnings date has been announced for RECURSION PHARMACEUTICALS, INC. (RXRX) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy RXRX? — Investment Thesis Summary

The quantitative profile for RECURSION PHARMACEUTICALS, INC. suggests caution. The quality score of 18/100 flags below-average profitability. The value score of 15/100 indicates premium valuation. Momentum is weak at 17/100, a headwind for near-term performance. High volatility (stability score 25/100) increases portfolio risk.

In summary, RECURSION PHARMACEUTICALS, INC. (RXRX) earns a Avoid rating with a composite score of 22.0/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on RXRX stock.

Related Resources for RXRX Investors

Explore more research and tools: RXRX vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare RXRX head-to-head with peers: RXRX vs AZN, RXRX vs SLGL, RXRX vs VMD.